Renovaro Inc. Stock

Equities

RENB

US29350E1047

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
0.97 USD +5.75% Intraday chart for Renovaro Inc. -14.16% -69.40%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2022 - Sales 2023 - Capitalization 34.41M
Net income 2022 -113M Net income 2023 -39M EV / Sales 2022 -
Net cash position 2022 1.99M Net Debt 2023 3.9M EV / Sales 2023 -
P/E ratio 2022
-0.89 x
P/E ratio 2023
-0.8 x
Employees 12
Yield 2022 *
-
Yield 2023
-
Free-Float 74.45%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.75%
1 week-14.16%
Current month-38.61%
1 month-55.30%
3 months-57.27%
6 months-66.78%
Current year-69.40%
More quotes
1 week
0.82
Extreme 0.82
1.17
1 month
0.82
Extreme 0.82
2.20
Current year
0.82
Extreme 0.82
5.25
1 year
0.39
Extreme 0.3928
5.25
3 years
0.39
Extreme 0.3928
13.78
5 years
0.39
Extreme 0.3928
13.78
10 years
0.39
Extreme 0.3928
13.78
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 18-01-22
Chief Tech/Sci/R&D Officer - 23-08-20
Chief Tech/Sci/R&D Officer - 15-12-31
Members of the board TitleAgeSince
Director/Board Member 58 19-12-31
Director/Board Member - 23-10-10
Director/Board Member 63 18-03-05
More insiders
Date Price Change Volume
24-05-17 0.97 +5.75% 153,451
24-05-16 0.9173 -3.17% 359,583
24-05-15 0.9473 -8.91% 237,061
24-05-14 1.04 -10.34% 258,894
24-05-13 1.16 +2.65% 236,060

Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT

More quotes
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
More about the company
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW